abstract |
This disclosure provides method of treatment comprising administering an AQGV peptide, or a functional analog thereof, to a human subject, the human subject optionally having impaired kidney function, wherein the treatment of administering an AQGV peptide comprises maintaining or improving hemodynamic stability in the human subject, such as a human subject suffering or considered suffering from Clarkson's disease (CLS). |